Skip Nav Destination
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations
Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993
Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma
Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal type
Anti–platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin
Up-regulated expression in nonhematopoietic tissues of the BCL2A1-derived minor histocompatibility antigens in response to inflammatory cytokines: relevance for allogeneic immunotherapy of leukemia
Issue Archive
December 1 2005
In this Issue
Table of Contents
INSIDE BLOOD
BLOOD WORK
PLENARY PAPERS
Shear stress affects the intracellular distribution of eNOS: direct demonstration by a novel in vivo technique
Caroline Cheng,Rien van Haperen,Monique de Waard,Luc C. A. van Damme,Dennie Tempel,Laurens Hanemaaijer,Gert W. A. van Cappellen,Joop Bos,Cornelis J. Slager,Dirk J. Duncker,Anton F. W. van der Steen,Rini de Crom,Rob Krams
REVIEWS IN TRANSLATIONAL HEMATOLOGY
CHEMOKINES, CYTOKINES, AND INTERLEUKINS
CLINICAL TRIALS AND OBSERVATIONS
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
Clinical Trials & Observations
Wolfgang Hiddemann,Michael Kneba,Martin Dreyling,Norbert Schmitz,Eva Lengfelder,Rudolf Schmits,Marcel Reiser,Bernd Metzner,Harriet Harder,Susanna Hegewisch-Becker,Thomas Fischer,Martin Kropff,Hans-Edgar Reis,Mathias Freund,Bernhard Wörmann,Roland Fuchs,Manfred Planker,Jörg Schimke,Hartmut Eimermacher,Lorenz Trümper,Ali Aldaoud,Reza Parwaresch,Michael Unterhalt
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype
Clinical Trials & Observations
Susanne Schnittger,Claudia Schoch,Wolfgang Kern,Cristina Mecucci,Claudia Tschulik,Massimo F. Martelli,Torsten Haferlach,Wolfgang Hiddemann,Brunangelo Falini
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations
Clinical Trials & Observations
Konstanze Döhner,Richard F. Schlenk,Marianne Habdank,Claudia Scholl,Frank G. Rücker,Andrea Corbacioglu,Lars Bullinger,Stefan Fröhling,Hartmut Döhner,for the AML Study Group (AMLSG)
Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance
Clinical Trials & Observations
Roel G. W. Verhaak,Chantal S. Goudswaard,Wim van Putten,Maarten A. Bijl,Mathijs A. Sanders,Wendy Hugens,André G. Uitterlinden,Claudia A. J. Erpelinck,Ruud Delwel,Bob Löwenberg,Peter J. M. Valk
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA
Clinical Trials & Observations
Joan Bladé,Laura Rosiñol,Ana Sureda,Josep M. Ribera,Joaquín Díaz-Mediavilla,José García-Laraña,M. Victoria Mateos,Luis Palomera,Javier Fernández-Calvo,Josep M. Martí,Pilar Giraldo,Félix Carbonell,Manel Callís,Jesús Trujillo,Santiago Gardella,M. Jesús Moro,Abelardo Barez,Alfons Soler,Llorenç Font,Montserrat Fontanillas,Jesús San Miguel,for Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA)
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993
Clinical Trials & Observations
Jacob M. Rowe,Georgina Buck,Alan K. Burnett,Raj Chopra,Peter H. Wiernik,Susan M. Richards,Hillard M. Lazarus,Ian M. Franklin,Mark R. Litzow,Niculae Ciobanu,H. Grant Prentice,Jill Durrant,Martin S. Tallman,Anthony H. Goldstone,for ECOG and the MRC/NCRI Adult Leukemia Working Party
Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia
Clinical Trials & Observations
Rosemary E. Gale,Robert Hills,Arnold R. Pizzey,Panagiotis D. Kottaridis,David Swirsky,Amanda F. Gilkes,Elizabeth Nugent,Kenneth I. Mills,Keith Wheatley,Ellen Solomon,Alan K. Burnett,David C. Linch,David Grimwade,for the NCRI Adult Leukaemia Working Party
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma
Clinical Trials & Observations
Sagar Lonial,Edmund K. Waller,Paul G. Richardson,Sundar Jagannath,Robert Z. Orlowski,Cynthia R. Giver,David L. Jaye,Dixil Francis,Sara Giusti,Claire Torre,Bart Barlogie,James R. Berenson,Seema Singhal,David P. Schenkein,Dixie-Lee W. Esseltine,Jessica Anderson,Hugh Xiao,Leonard T. Heffner,Kenneth C. Anderson,for the SUMMIT/CREST Investigators
Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal type
Clinical Trials & Observations
Tae Min Kim,Yeon Hee Park,Sang-Yoon Lee,Ji-Hoon Kim,Dong-Wan Kim,Seock-Ah Im,Tae-You Kim,Chul Woo Kim,Dae Seog Heo,Yung-Jue Bang,Kee-Hyun Chang,Noe Kyeong Kim
Anti–platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin
Clinical Trials & Observations
Theodore E. Warkentin,Richard J. Cook,Victor J. Marder,Jo-Ann I. Sheppard,Jane C. Moore,Bengt I. Eriksson,Andreas Greinacher,John G. Kelton
GENE THERAPY
HEMATOPOIESIS
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
IMMUNOBIOLOGY
NEOPLASIA
p130Cas mediates the transforming properties of the anaplastic lymphoma kinase
Chiara Ambrogio,Claudia Voena,Andrea D. Manazza,Roberto Piva,Ludovica Riera,Laura Barberis,Carlotta Costa,Guido Tarone,Paola Defilippi,Emilio Hirsch,Elisabetta Boeri Erba,Shabaz Mohammed,Ole N. Jensen,Giorgio Palestro,Giorgio Inghirami,Roberto Chiarle
Phenotypic and functional analyses of dendritic cells in patients with lymphoproliferative disease of granular lymphocytes (LDGL)
Renato Zambello,Tamara Berno,Giovanna Cannas,Ilenia Baesso,Gianni Binotto,Emanuela Bonoldi,Pierantonio Bevilacqua,Marta Miorin,Monica Facco,Livio Trentin,Carlo Agostini,Gianpietro Semenzato
NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia
Shinya Kimura,Haruna Naito,Hidekazu Segawa,Junya Kuroda,Takeshi Yuasa,Kiyoshi Sato,Asumi Yokota,Yuri Kamitsuji,Eri Kawata,Eishi Ashihara,Yohei Nakaya,Haruna Naruoka,Tatsushi Wakayama,Kimio Nasu,Tetsuo Asaki,Tomoko Niwa,Kazuko Hirabayashi,Taira Maekawa
Up-regulated expression in nonhematopoietic tissues of the BCL2A1-derived minor histocompatibility antigens in response to inflammatory cytokines: relevance for allogeneic immunotherapy of leukemia
Brief Report
Freke M. Kloosterboer,Simone A. P. van Luxemburg-Heijs,Ronald A. van Soest,H. M. Esther van Egmond,Roel Willemze,J. H. Frederik Falkenburg
PHAGOCYTES
RED CELLS
STEM CELLS IN HEMATOLOGY
TRANSPLANTATION
Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor β genotype of donor
Ming-Tseh Lin,Barry Storer,Paul J. Martin,Li-Hui Tseng,Bryan Grogan,Pei-Jer Chen,Lue P. Zhao,John A. Hansen
-
Cover Image
Cover Image
![issue cover]()
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
